Floatz logo

Fosaprepitant Dimeglumine

Vomiting

University of Southern CaliforniaPhase 1Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Vomiting cohort.

Asset / SponsorPhaseRating
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Rush University Medical Center
Phase 4A
Zofran
University of South Florida
Phase 4BBB
DEXAMETHASONE
Jun Zhu
Phase 4BB
Tropisetron
Jun Zhu
Phase 4BB
Olanzapine
Rush University Medical Center
Phase 3BB

View all 19 →

Same molecule, other indications

Fosaprepitant Dimeglumine is also rated in:

Prevention of Nausea and Vomiting Caused by Highly Emetogenic ChemotherapyDormant
CC
Indicative ·
43 / 100
View asset →
cancer of unknown primary siteDormant
C
Indicative ·
33 / 100
View asset →
NauseaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →